Chlamydia Infections - Pipeline Insight, 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 31, 2019--The “Chlamydia Infections - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Chlamydia Infections - Pipeline Insight, 2019 offers a comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Chlamydia Infections development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
ScopeThe report provides a snapshot of the pipeline development for Chlamydia Infections The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Chlamydia Infections The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Chlamydia Infections The report also covers the dormant and discontinued pipeline projects related to Chlamydia Infections
1. Report Introduction
2. Chlamydia Infections Overview
3. Pipeline TherapeuticsAn Overview of Pipeline Products for Chlamydia Infections
4. Comparative Analysis
5. Products in Clinical StageProduct Description Research and Development Product Development Activities
6. Products in Pre-Clinical and Discovery StageProduct Description Research and Development Product Development Activities
7. Therapeutic AssessmentAssessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type
8. Inactive ProductsProduct Description Research and Development Product Development Activities
Companies FeaturedAbera Bioscience AB Evofem Inc. Lead Discovery Center GmbH Merck & Co. Inc. NanoBio Corp. Prokarium Ltd. QureTech Bio AB SATT IDF Innov S.A.S Selecta Biosciences Inc. SIGA Technologies Inc.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/2rffbq/chlamydia?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190131005810/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Infectious Diseases Drugs,Sexual and Reproductive Health Drugs
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/31/2019 01:43 PM/DISC: 01/31/2019 01:43 PM